Fulcrum Therapeutics Inc. (FULC) Misses Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results
May 9, 2022 7:00 AM EDTInitial data from Phase 1b trial of FTX-6058 in sickle cell disease to be presented at the EHA 2022 CongressÂ
Phase 3 REACH trial of losmapimod in FSHD expected to begin in 2Q 2022
Conference call scheduled for 8:00 a.m. ET today
CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics,... More
